PPARgamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation
- 31 December 2008
- journal article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 70 (2), 419-423
- https://doi.org/10.1016/j.mehy.2006.12.064
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combinationEuropean Journal of Cancer, 2006
- Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and RosiglitazoneInternational Journal of Cancer, 2006
- Vascular endothelial growth factor signalling in endothelial cell survival: A role for NFκBBiochemical and Biophysical Research Communications, 2006
- Sunitinib: A newly approved small-molecule inhibitor of angiogenesisDrugs of Today, 2006
- Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsAnnals Of Oncology, 2005
- Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancerInternational Journal of Cancer, 2005
- PPARγ as a therapeutic target for tumor angiogenesis and metastasisCancer Biology & Therapy, 2005
- Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor γ and hepatocyte nuclear factor 4αBiochemical and Biophysical Research Communications, 2003
- Activation of PPARγ increases PTEN expression in pancreatic cancer cellsBiochemical and Biophysical Research Communications, 2003
- Leptin Induces Endothelial Cell Migration Through Akt, Which Is Inhibited by PPARγ-LigandsHypertension, 2002